Flagship Biosciences chooses Harte Hanks as marketing solutions partner.
June 03 2020 - 4:05PM
Harte Hanks, Inc. (NYSE: HHS), a leading behavioral marketing
company, announced today that it has been selected by Flagship
Biosciences to provide strategic marketing solutions in developing
a new customer acquisition program.
Flagship Biosciences is a leader in technology-driven tissue
analysis, and provides expert tissue data insights to
pharmaceutical, biotechnology and clinical diagnostic
companies.
Harte Hanks will be developing a targeted, multi-channel
campaign including email, digital advertising and content creation
to help Flagship Biosciences engage priority audiences, nurture
leads and connect with potential clients.
Through extensive behavioral research, Harte Hanks has laid out
a strategy for communicating to key decision-makers in Flagship’s
target biotechnology market. The campaign will convey Flagship’s
value proposition as a trusted research partner that can accelerate
drug development and improve patient outcomes. For the campaign
launch, Harte Hanks will provide research, strategic planning,
creative messaging and execution.
“It’s important that we get our message in front of the critical
decision-makers at these pharmaceutical companies and show how we
can help improve their clinical results,” said Flagship Biosciences
CEO Trevor Johnson. “We chose Harte Hanks for their proven record
and expertise in connecting with prospects on a one-to-one level
through targeted marketing campaigns.”
“We are thrilled to have this opportunity to support Flagship
Biosciences and build a partnership with such an innovator in their
field,” said Dana Adams, Chief Client Officer, Harte Hanks. “We’ll
bring our expertise in pharma/biosciences and BtoB marketing
credentials to bear, and we’re confident that our experience in
successful, award-winning lead generation campaigns will help this
leading-edge company reach their growth goals this year and
beyond.”
About Harte HanksAt Harte Hanks, we're building
a modern, behavioral marketing company. We marry our data-driven
understanding of human behavior with a seamless connection to the
customer. Through digital, direct, sampling, fulfillment and
customer care, we manage a full customer experience. And in doing
so, we are shortening the distance between behavior and action.
Harte Hanks has 2,400 employees delivering solutions in North
America, Asia-Pacific and Europe. For more information, visit Harte
Hanks at hartehanks.com, call 800-456-9748, or email us at
pr@hartehanks.com.
As used herein, “Harte Hanks” refers to Harte Hanks, Inc. and/or
its applicable operating subsidiaries, as the context may require.
Harte Hanks’ logo and name are trademarks of Harte Hanks.
About Flagship BiosciencesFounded in 2009 and
headquartered in Westminster, Colorado, Flagship Biosciences, Inc.
is a technology-driven tissue analysis services company delivering
the most accurate and informative data available. It is
revolutionizing tissue analysis to improve drug development and
diagnostics using the power of AI with a consultative approach.
Flagship’s services and technology dramatically improve on the data
and interpretation from traditional pathology methods, eliminating
variability and bringing new insights to tissue analysis results.
With expert scientific consultation on every project, Flagship’s
team interprets results, contextualizes tissue biology, and
identifies the best course for success. flagshipbio.com
Contact:Jennifer London(508) 894 -
1563Jen.London@hartehanks.com
Harte Hanks (NYSE:HHS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Harte Hanks (NYSE:HHS)
Historical Stock Chart
From Jan 2024 to Jan 2025